|
Taglich Brothers Initiates Coverage
on GammaCan International, Inc.
NEW YORK, September 21, 2007 – Taglich Brothers, Inc.
announces it initiated coverage of GammaCan International, Inc. (OTC BB:
GCAN)).
GammaCan Internatinal, Inc., headquartered in Kiryat
Ono, Israel, has been active in the development of intravenous
immunoglobulin therapy for cancer since 2004. The company’s lead
product, VitiGam™, is aimed at treating stage III and IV melanoma with
immunotherapy. The company is also developing an anti-angiogenesis agent
as a cancer treatment.
The complete 18-page report is available at
www.taglichbrothers.com.
Taglich Brothers, Inc. is a full-service broker dealer
focused exclusively on microcap companies. The Company defines the
microcap segment of the equity market as companies with less than $250
million in market capitalization. Taglich Brothers currently offers
institutional and retail brokerage services, investment banking and
comprehensive research coverage to the investment community.
The information and statistical data contained herein
have been obtained from sources, which we believe to be reliable but in
no way are warranted by us as to accuracy or completeness. We do not
undertake to advise you as to changes in figures or our views. This is
not a solicitation of any order to buy or sell. Taglich Brothers, Inc.
is fully disclosed with its clearing firm, Pershing, LLC, is not a
market maker and does not sell to or buy from customers on a principal
basis. The above statement is the opinion of Taglich Brothers, Inc. and
is not a guarantee that the target price for the stock will be met or
that predicted business results for the company will occur. There may be
instances when fundamental, technical and quantitative opinions
contained in this report are not in concert. We, our affiliates, any
officer, director or stockholder or any member of their families may
from time to time purchase or sell any of the above-mentioned or related
securities. Analysts and members of the Research Department are
prohibited from buying or selling securities issued by the companies
that Taglich Brothers, Inc. has a research relationship with, except if
ownership of such securities was prior to the start of such
relationship, then an Analyst or member of the Research Department may
sell such securities after obtaining expressed written permission from
the Director of Research. As of the date of this report no Taglich
Brothers, Inc. employees had a position in the stock of the Company
mentioned in this report: All research issued by Taglich Brothers, Inc.
is based on public information. The company paid a $5,000 (USD)
engagement fee in August, 2007 and will, commencing upon distribution of
our initial report, pay $1,750 (USD) per month for the creation and
dissemination of research reports. For further information and Taglich
Brothers, Inc. ownership data please refer to each individual report.
|
